Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II preemptive CMV treatment guided by virologic monitoring and CMV-specific CD8 T-cell quantification after allogeneic hematopoietic transplantation
2011-001449-34Phase 2Completed
- Sponsor
- INCLIVA Biomedical Research Institute
- Start
- Jun 2011
- Modality
- Small Molecules, Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of ganciclovir, valganciclovir and foscarnet sodium in cytomegalovirus disease (CMV), sponsored by INCLIVA Biomedical Research Institute. Primary endpoint: CMV blood negativity at end of treatment without relapse. Started Jun 2011; status: completed.
02
Drugs
ganciclovirvalganciclovirfoscarnet sodium
03
Conditions
cytomegalovirus disease (CMV)
Beyond the preview
Go deeper on 2011-001449-34.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2011-001449-34.